PPARD and hepatocellular carcinoma: Accordingly, PPARδ agonist (GW501516) abolished the IL6-driven acute phase reaction in human hepatoma cells and rat primary hepatocytes by inhibition of STAT3 [11], preventing systemic inflammation via reduction in mRNA expression (α1-anti-chymotrypsin, α2-acid glycoprotein, β-fibrinogen, α2-macroglobulin) and secretion of C-reactive protein, whereas genetic depletion of PPARδ reversed these effects.